Translational advances in pancreatic ductal adenocarcinoma therapy

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently detected at advanced stages, limiting treatment options to systemic chemotherapy with modest clinical responses. Here, we review recent advances in targeted therapy and immunotherapy for treating subtypes of PDAC with diverse molecular alterations. We focus on the current preclinical and clinical evidence supporting the potential of these approaches and the promise of combinatorial regimens to improve the lives of patients with PDAC. Hosein et al. discuss the current therapeutic landscape in pancreatic cancer as well as the translational and clinical implications and the challenges to overcome.

Automated summary

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is often diagnosed at advanced stages, leading to limited treatment options. Recent advancements in targeted therapy and immunotherapy for different subtypes of PDAC are reviewed in this article, with a focus on the current preclinical and clinical evidence supporting these approaches and the potential of combination treatments.